The second two-day 'pharma summit' organised by the
Confederation of Indian Industry (CII) got underway
in Mumbai with a key note address by Dr Pushpa Bhargave,
former director of the Centre for Cellular and Molecular
Bhargave said that Asia's biotech industry was the fastest-growing
sector in the global pharmaceutical industry and given
India's technical power, capabilities, favourable infrastructure
and requisite value structure, India could easily become
the leader in drug manufacturing.
visualised opportunities for India in the area of vaccines,
DNA probes, MAB's for diagnosis, biochemical sensors
for diagnosis, drugs through genetically modified microbes,
peptide drugs and drugs through marine sources.
Bhargave outlined several initiatives that the government
as well as industry should undertake and stressed the
need for a people-oriented role involving the medicare
industry for developing a health and medical policy
for the country.
an overview of the 'projections and imperatives' of
the pharma industry, Shalini Pillay, associate director,
KPMG Advisory Services Pvt Ltd emphasised the need for
networking within the pharmaceutical industry and growth
strategies to boost R & D and sales productivity.
For leveraging the opportunities in the pharma industry
mergers and acquisitions would boost the top line and
bring in new products.
networked pharma industry, according to Satish Reddy,
MD & COO, Dr Reddy's Laboratories Ltd, is an emerging
growth model and should cater to increased shareholder
value, economic value and net profit. The projections
and imperatives study aims at identifying competition
among Indian players eliminate price erosion, sustainability
of growth and profitability, increased investment requirements
and finally transitioning to a global position.
also talked about the emerging trends and the Indian
pharma market, where big pharma companies are under
pressure because of increased research and development
expenditure, rising costs, poorly understood new technologies
and the need for innovations.
overcome these pressures, Sunil Mehra, vice president,
health care group, DSP Merrill Lynch, suggested fully
skills and access larger international markets by exploiting
the global opportunity in generics and develop brand
/ specialty businesses.